MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats

Peptides

Volumn 28, Issue 10, 2007, Pages 2009-2015

  Castellano, Jessica M ^a   Batrynchuk, Jody ^a   Dolbeare, Kristine ^b   Verma, Vaneeta ^a   Mann, Amandeep ^a   Skoblenick, Kevin J ^a   Johnson, Rodney L ^b   Mishra, Ram K ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

6 Hydroxydopamine; Dopamine; Melanocyte stimulating hormone release inhibiting factor 1 (MIF 1); Parkinson's disease; Tardive dyskinesia; Vacuous chewing movements

Indexed keywords

APOMORPHINE; HALOPERIDOL; OXIDOPAMINE; PROLYLLEUCYLGLYCINAMIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; IN VIVO STUDY; MALE; MASTICATION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; TARDIVE DYSKINESIA;

ANIMALS; APOMORPHINE; BEHAVIOR, ANIMAL; HALOPERIDOL; MALE; MASTICATION; MOLECULAR MIMICRY; MSH RELEASE-INHIBITING HORMONE; OXIDOPAMINE; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA;

ANIMALIA; RATTUS;

EID: 34548699670     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.07.026     Document Type: Article

References (52)

1. 2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 97 (2000) 8104-8109
2. Barbeau A. Potentiation of levodopa effect by intravenous l-prolyl-l-leucyl-glycine amide in man. Lancet 2 (1975) 683-684
3. Barbeau A. Peptides in Parkinson's disease. Adv Exp Med Biol 113 (1978) 101-110
4. 3H]apomorphine binding sites. Gen Pharmacol 14 (1983) 609-614
5. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., and Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 41 (2001) 237-260
6. Case T.C., Snider S.R., Hruby V.J., and Rockway T. Active and inactive l-prolyl-l-leucyl glycinamide synthetic analogs in rat models of levodopa-treated Parkinson's disease. Life Sci 36 (1985) 2531-2537
7. Castellano J.M., Paladino P., Skoblenick K.J., Dyck B.A., Johnson R.L., and Mishra R.K. Increased expression of protein kinase B by the endogenous brain peptide l-Pro-l-Leu-glycinamide vol. 34 (2004), Society for Neuroscience, San Diego, CA p. 113.12
8. Chiu S., Paulose C.S., and Mishra R.K. Effect of l-prolyl-l-leucyl-glycinamide (PLG) on neuroleptic-induced catalepsy and dopamine/neuroleptic receptor bindings. Peptides 2 (1981) 105-111
9. Chiu S., Wong Y.W., Wan Y.P., Chiu P., and Mishra R.K. Are the pharmacological effects of l-prolyl-l-leucyl-glycinamide (PLG) mediated through specific receptor mechanisms?. Prog Neuropsychopharmacol Biol Psychiatry 7 (1983) 739-742
10. Christopoulos A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov 1 (2002) 198-210
11. Christopoulos A., and Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54 (2002) 323-374
12. Cotzias G.C., Van Woert M.H., and Schiffer L.M. Aromatic amino acids and modification of parkinsonism. N Engl J Med 276 (1967) 374-379
13. Deumens R., Blokland A., and Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 175 (2002) 303-317
14. Dolbeare K., Pontoriero G.F., Gupta S.K., Mishra R.K., and Johnson R.L. Synthesis and dopamine receptor modulating activity of 3-substituted gamma-lactam peptidomimetics of l-prolyl-l-leucyl-glycinamide. J Med Chem 46 (2003) 727-733
15. Drucker G.E., Ritzmann R.F., Wichlinski L.J., Engh K., Gordon J.H., and Fields J.Z. Prevention and reversal of dopamine receptor supersensitivity by cyclo(leucyl-glycyl) (CLG): biphasic dose-response curves. Pharmacol Biochem Behav 47 (1994) 141-145
16. Egan M.F., Apud J., and Wyatt R.J. Treatment of tardive dyskinesia. Schizophr Bull 23 (1997) 583-609
17. Ehrensing R.H. Letter: lithium and M.R.I.H. in tardive dyskinesia. Lancet 2 (1974) 1459-1460
18. Ehrensing R.H., and Kastin A.J. Melanocyte-stimulating hormone-release inhibiting hormone as a antidepressant. A pilot study. Arch Gen Psychiatry 30 (1974) 63-65
19. Ehrensing R.H., Kastin A.J., Larsons P.F., and Bishop G.A. Melanocyte-stimulating-hormone release-inhibiting factor-I and tardive dyskinesia. Dis Nerv Syst 38 (1977) 303-307
20. Ehrensing R.H., Kastin A.J., Wurzlow G.F., Michell G.F., and Mebane A.H. Improvement in major depression after low subcutaneous doses of MIF-1. J Affect Disord 31 (1994) 227-233
21. Evans M.C., Pradhan A., Venkatraman S., Ojala W.H., Gleason W.B., Mishra R.K., et al. Synthesis and dopamine receptor modulating activity of novel peptidomimetics of l-prolyl-l-leucyl-glycinamide featuring alpha,alpha-disubstituted amino acids. J Med Chem 42 (1999) 1441-1447
22. Gunne L.M., Growdon J., and Glaeser B. Oral dyskinesia in rats following brain lesions and neuroleptic drug administration. Psychopharmacology (Berl) 77 (1982) 134-139
23. Hara C., and Kastin A.J. Acute administration of MIF-1 or Tyr-MIF-1 inhibits haloperidol-induced catalepsy in rats. Pharmacol Biochem Behav 24 (1986) 1785-1787
24. Hara C., and Kastin A.J. Biphasic effects of MIF-1 and Tyr-MIF-1 on apomorphine-induced stereotypy in rats. Pharmacol Biochem Behav 25 (1986) 757-761
25. Hashimoto T., Ross D.E., Gao X.M., Medoff D.R., and Tamminga C.A. Mixture in the distribution of haloperidol-induced oral dyskinesias in the rat supports an animal model of tardive dyskinesia. Psychopharmacology (Berl) 137 (1998) 107-112
26. Hudson J.L., van Horne C.G., Stromberg I., Brock S., Clayton J., Masserano J., et al. Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res 626 (1993) 167-174
27. Ikeda H., Adachi K., Hasegawa M., Sato M., Hirose N., Koshikawa N., et al. Effects of chronic haloperidol and clozapine on vacuous chewing and dopamine-mediated jaw movements in rats: evaluation of a revised animal model of tardive dyskinesia. J Neural Transm 106 (1999) 1205-1216
28. 2 analogues possessing cyclic amino acid residues at the C-terminal position. J Med Chem 29 (1986) 2100-2104
29. 2 analogues modified at the prolyl residue and evaluation of their effects on the receptor binding activity of the central dopamine receptor agonist, ADTN. J Med Chem 29 (1986) 2104-2107
30. Kastin A.J., and Barbeau A. Preliminary clinical studies with l-prolyl-l-leucyl-glycine amide in Parkinson's disease. Can Med Assoc J 107 (1972) 1079-1081
31. Kostrzewa R.M., Kastin A.J., and Sobrian S.K. Potentiation of apomorphine action in rats by l-prolyl-l-leucyl-glycine amide. Pharmacol Biochem Behav 9 (1978) 375-378
32. 2 (PLG, MIF-1). Peptides 19 (1998) 403-406
33. Mishra R.K., Chiu S., Chiu P., and Mishra C.P. Pharmacology of l-prolyl-l-leucyl-glycinamide (PLG): a review. Methods Find Exp Clin Pharmacol 5 (1983) 203-233
34. 2 (PLG). Peptides 18 (1997) 1209-1215
35. 2 receptor by l-pro-l-leu-glycinamide (PLG) analogue 3(R)-(N-l-prolylamino)-2-oxo-1-pyrrolidineacetamide. Prog Neuropsychopharmacol Biol Psychiatry 14 (1990) 821-827
36. Mycroft F.J., Bhargava H.N., and Wei E.T. Pharmacological activities of the MIF-1 analogues Pro-Leu-Gly, Tyr-Pro-Leu-Gly and peptide. Peptides 8 (1987) 1051-1055
37. Ott M.C., Mishra R.K., and Johnson R.L. Modulation of dopaminergic neurotransmission in the 6-hydroxydopamine lesioned rotational model by peptidomimetic analogues of l-prolyl-l-leucyl-glycinamide. Brain Res 737 (1996) 287-291
38. Rajakumar G., Naas F., Johnson R.L., Chiu S., Yu K.L., and Mishra R.K. Down-regulation of haloperidol-induced striatal dopamine receptor supersensitivity by active analogues of l-prolyl-l-leucyl-glycinamide (PLG). Peptides 8 (1987) 855-861
39. Reed G.W., Olson G.A., and Olson R.D. The Tyr-MIF-1 family of peptides. Neurosci Biobehav Rev 18 (1994) 519-525
40. Rogoza R.M., Fairfax D.F., Henry P., Marandi S., Khan R.F., Gupta S.K., et al. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia. Synapse 54 (2004) 156
41. Sachdev P.S. The current status of tardive dyskinesia. Aust N Z J Psychiatry 34 (2000) 355-369
42. 2 receptor ontogeny. Peptides 10 (1989) 35-39
43. Schleimer S.B., Johnston G.A., and Henderson J.M. Novel oral drug administration in an animal model of neuroleptic therapy. J Neurosci Methods 146 (2005) 159-164
44. 2 receptors. Proc Natl Acad Sci USA 97 (2000) 7673-7675
45. Sharma S., Paladino P., Gabriele J., Saeedi H., Henry P., Chang M., et al. Pro-Leu-glycinamide and its peptidomimetic, PAOPA, attenuate haloperidol induced vacuous chewing movements in rat: a model of human tardive dyskinesia. Peptides 24 (2003) 313-319
46. Smith J.R., and Morgan M. The effects of prolyl-leucyl-glycine amide on drug-induced rotation in lesioned rats. Gen Pharmacol 13 (1982) 203-207
47. 2 receptor: evidence for modulation of agonist affinity states in bovine striatal membranes. J Neurochem 50 (1988) 960-968
48. Takeuchi H., Ishigooka J., Kobayashi K., Watanabe S., and Miura S. Study on the suitability of a rat model for tardive dyskinesia and the preventive effects of various drugs. Prog Neuropsychopharmacol Biol Psychiatry 22 (1998) 679-691
49. Turrone P., Remington G., Kapur S., and Nobrega J.N. Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats. Biol Psychiatry 57 (2005) 406-411
50. Turrone P., Remington G., and Nobrega J.N. The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy?. Neurosci Biobehav Rev 26 (2002) 361-380
51. Verma V., Mann A., Costain W., Pontoriero G., Castellano J.M., Skoblenick K., et al. Modulation of agonist binding to human dopamine receptor subtypes by l-prolyl-l-leucyl-glycinamide and a peptidomimetic analog. J Pharmacol Exp Ther 315 (2005) 1228-1236
52. Volavka J., Czobor P., Sheitman B., Lindenmayer J.P., Citrome L., McEvoy J.P., et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 159 (2002) 255-262